Surgical Transparency

Institutional Audit &
Transactional Evidence

We don't just share results; we provide mathematical evidence.

Every trade, slippage point, and operational cost documented across 72 months of rolling analysis. Real execution friction built into every data point. Zero theoretical assumptions—only what an institutional allocator can genuinely execute.

Audit Confidence Level

The Evidence Framework

Why This Audit Matters

Built for Real-World Execution

Every trade includes 10 basis points slippage and Finvasia's actual tax-optimized cost structure. This is not theoretical performance—it's the exact ROI an institutional allocator will execute when deploying capital through our infrastructure.

Tested Across Market Cycles

Market crash (2020), low volatility regime (2021), and high volatility stress (2023–25)—this audit proves consistent positive expectancy across all market conditions. Resilience is documented, not claimed.

Distinct Scaling DNA

E1, V1, and V2 differ fundamentally in their scaling logic and position-sizing DNA. The table below shows 12 overlapping 36-month windows—compare directly across all three models to understand architectural differentiation.

Complete Transactional Record

36-Month Rolling Performance Audit

Filter Strategy:

Analysis Window	E1 Capital Preservation		V1 Linear Compounding		V2 Titanium Scaling The Alpha Leader
	ROI %	Max DD	ROI %	Max DD	ROI %	Max DD

Methodology

Average metrics calculated across 12 overlapping rolling 36-month windows (2020 Q1 - 2025 Q3). Results demonstrate consistent positive expectancy irrespective of entry regime. Each model operates independently with proprietary risk parameters and scaling logic. Trade logs and execution details are gated for verified institutional partners. All data includes 10 points slippage per trade and Finvasia (Shoonya) tax-optimized execution costs. This represents the realistic performance expectancy for institutional allocators deploying capital through the LeoQuant infrastructure.